Literature DB >> 1287200

Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

J W Mandema1, D Verotta, L B Sheiner.   

Abstract

One major task in clinical pharmacology is to determine the pharmacokinetic-pharmacodynamic (PK-PD) parameters of a drug in a patient population. NONMEM is a program commonly used to build population PK-PD models, that is, models that characterize the relationship between a patient's PK-PD parameters and other patient specific covariates such as the patient's (patho) physiological condition, concomitant drug therapy, etc. This paper extends a previously described approach to efficiently find the relationships between the PK-PD parameters and covariates. In a first step, individual estimates of the PK-PD parameters are obtained as empirical Bayes estimates, based on a prior NONMEN fit using no covariates. In a second step, the individual PK-PD parameter estimates are regressed on the covariates using a generalized additive model. In a third and final step, NONMEM is used to optimize and finalize the population model. Four real-data examples are used to demonstrate the effectiveness of the approach. The examples show that the generalized additive model for the individual parameter estimates is a good initial guess for the NONMEM population model. In all four examples, the approach successfully selects the most important covariates and their functional representation. The great advantage of this approach is speed. The time required to derive a population model is markedly reduced because the number of necessary NONMEM runs is reduced. Furthermore, the approach provides a nice graphical representation of the relationships between the PK-PD parameters and covariates.

Entities:  

Mesh:

Year:  1992        PMID: 1287200     DOI: 10.1007/bf01061469

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  4 in total

1.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

2.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 3.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

4.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

  4 in total
  205 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

2.  Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection.

Authors:  S Sadray; E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

3.  Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.

Authors:  Y Merlé; A Mallet; E Schmautz
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

4.  Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

Authors:  K G Kowalski; M M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

5.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

6.  The effect of collinearity on parameter estimates in nonlinear mixed effect models.

Authors:  P L Bonate
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

7.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

8.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

9.  Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers.

Authors:  Carol Cronenberger; Diane R Mould; Hans-Juergen Roethig; Mohamadi Sarkar
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

10.  Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach.

Authors:  Cécile Gérard; Jeanick Stocco; Anne Hulin; Benoit Blanchet; Céline Verstuyft; François Durand; Filomena Conti; Christophe Duvoux; Michel Tod
Journal:  AAPS J       Date:  2014-02-14       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.